Navigation Links
Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
Date:1/5/2011

CRANBURY, N.J., Jan. 5, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that  Chairman and Chief Executive Officer John F. Crowley will be presenting a business update and a review of the Company's expected key milestones for 2011 at the upcoming 29th Annual J.P. Morgan Healthcare Conference.  Mr. Crowley's presentation is scheduled to begin on Tuesday, January 11 at 3:00 p.m. PST.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics web site, http://www.amicustherapeutics.com.  Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.

About Amicus TherapeuticsAmicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of rare diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease.  CONTACT:Amicus Therapeutics(609) 662-2000ir@amicustherapeutics.com FOLD-G


'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
(Date:5/25/2016)... 2016 Digital Health Dialog, LLC dba ... the US Patent and Trademark Office of U.S. ... processes for electronic opt-­in and processing of discount ... HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to opt­-in ...
(Date:5/24/2016)... -- Niederländische Chirurgen haben eine innovative ... erlaubt, ihre Expertise weltweit zu teilen und so ... mit einer Instant-Messaging-Funktion und der Möglichkeit, in einem ... Afrika, Asien und den USA ... Information und Weiterbildung   "MDLinking ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... treatment for eating disorders, is opening a brand new child and adolescent residential ... 8-17 and their families with even more specialized eating disorder treatment and access ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical Center ... Golf Club in Cypress. With the help of community partners, the event organizers raised ... renews hope for wounded service members and their families through health, wellness, and therapeutic ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian Mehling, ... The conference was held during May 5-6, 2016 in Chicago, IL, USA. Dr. ...
(Date:5/26/2016)... Scotch Plains, NJ (PRWEB) , ... May 26, ... ... year being recognized as an NJ Top Doc! Along with his wonderful accolades ... to excellence in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
Breaking Medicine News(10 mins):